- Global Pharma News & Resources

6,000 Subjects Analysed by AMRA Now Available for Researchers Through UK Biobank

UK Biobank, a major national and international health resource, and AMRA, the international leader in body composition analysis, are proud to announce that 6,000 subjects analysed for body composition are now available through the globally-acclaimed health study. Scientists and researchers intending to use the data in research related to prevention, diagnosis, and treatment of illness are now able to apply for unlimited access via the UK Biobank website.


For ten years, UK Biobank has gathered a wide range of crucial information about participants’ health and well-being, including genetic data and the health record data for its 500,000 participants. In 2016, UK Biobank launched the world’s largest health imaging study, focused on dedicated imaging of the brain, heart, bones, carotid arteries, and body composition of 100,000 UK Biobank participants. 


AMRA was selected to perform the precise fat and muscle measurement of all 100,000 UK Biobank body MRIs, to be completed over the course of several years of data collection. The company’s analysis of the first 6,000 MRI scans from UK Biobank has already resulted in several accepted abstract presentations by AMRA, clearly showing a link between body composition and coronary heart disease[i], type 2 diabetes[ii], sarcopenia[iii] and an increased healthcare burden associated with visceral obesity.[iv]


Through the phased release of these extensive datasets, UK Biobank will provide scientists and researchers with the ability to support clinical trials and produce the new biomarkers that will allow for the improved prevention, diagnosis, and treatment of a wide range of diseases, from diabetes to dementia. This aligns with one of AMRA’s goals of redefining obesity through better understanding of individual metabolic risk, and to ultimately assist in the prediction and prevention of disease.


Tommy Johansson, Chief Executive Officer of AMRA, commented, “I’m very proud that AMRA was chosen to work with UK Biobank on a project of such scale and value to the scientific community. As the largest imaging study of its kind and one of the most comprehensive, I’m looking forward to watching and learning how this initial data set – and the many scheduled to follow – will be used to help support clinical trials, improve treatments, and ultimately prevent disease. 6,000 MRI scans analysed and available for researchers, with only 94,000 to go!”